Andere talen Intellia Therapeutics, Inc.

Aandelen

NTLA

US45826J1051

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
20,02 ^USD	-5,43%		-6,10%	-34,34%

15/04	Intellia Therapeutics, Inc. Stelt Michael P. Dube aan als hoofd boekhouding	CI
25/03	Intellia Therapeutics beëindigt ontwikkelingsovereenkomst met Regeneron Pharmaceuticals	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Intellia Therapeutics : Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine - Form 8-K	15/04
Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer	15/04
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	25/03
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	22/03
Intellia Therapeutics Ends Co-Development Agreement With Regeneron	22/03
Intellia Therapeutics : Termination of Material Agreement - Form 8-K	22/03
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy	18/03
Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy	18/03
North American Morning Briefing : Traders Await -2-	26/02
Intellia Therapeutics Q4 Loss Widens	22/02
Intellia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress	22/02
Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
Intellia Therapeutics, ReCode to Develop Therapies For Cystic Fibrosis	15/02
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis	15/02
Intellia Therapeutics, Inc. and ReCode Therapeutics Announces Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis	15/02
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates	15/02
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates	14/02
AvenCell Announces First Patient Dosed in a Phase IA Study with lead product candidate AVC-201, a Novel Allogeneic CD123-Directed Switchable CAR-T Investigational Therapy	07/02
Intellia Therapeutics Says Investigational Hereditary Angioedema Treatment Shows Promise in Phase 1 Study	01/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Intellia Therapeutics, Inc.

Aandelen

NTLA

US45826J1051

Andere talen

Filters